Categories: News

PatchMD Introduces New GLP-1 Support Patches for Individuals on Weight Loss Medications

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

HENDERSON, NV, March 12, 2025 (GLOBE NEWSWIRE) —

PatchMD, a leading innovator in transdermal nutrient delivery, is excited to announce the launch of its new GLP-1 Support Patch Collection—a targeted solution designed to complement individuals using GLP-1 receptor agonist medications such as Ozempic, Wegovy, and Mounjaro for weight management. This new collection is available now at www.patchmd.com/glp-1-patches.html.

GLP-1 receptor agonists are transforming the landscape of medical weight loss, yet many individuals experience nutrient deficiencies and side effects such as nausea and appetite suppression. PatchMD’s topical patches provide an innovative way to supplement essential vitamins, minerals, and other nutrients without the need for pills or powders—ensuring optimal absorption and convenience.

Why PatchMD’s GLP-1 Patches? Unlike traditional oral supplements that pass through the digestive system, PatchMD’s GLP-1 patches deliver nutrients directly through the skin, bypassing potential gastrointestinal discomfort and absorption issues. This makes them an ideal choice for individuals experiencing nausea, reduced appetite, or other side effects commonly associated with GLP-1 medications.

PatchMD’s GLP-1 Support Collection includes:

  • Essential Nutrient Support – Formulated to replenish key vitamins and minerals for overall well-being.
  • Nausea Relief Patch – Designed to help manage nausea, a common side effect of GLP-1 medications.
  • Appetite Suppression Patch – Supports metabolic health and appetite control in a natural, balanced way.
  • Metabolism Plus Patch – Provides additional energy and metabolic support to complement weight management.

The Latest in GLP-1 Research & Innovation As a trusted name in transdermal supplementation, PatchMD remains at the forefront of scientific advancements in weight management support.

We recently published detailed insights on two next-generation GLP-1 medications, providing valuable information for individuals seeking the latest updates in the field:

About PatchMD PatchMD is a leader in transdermal supplement technology, offering a variety of vitamin patches that bypass the digestive system for superior absorption. Our patches are lactose-free, gluten-free, and non-GMO, making them an excellent option for those with dietary restrictions. By providing an easy, effective, and hassle-free way to get essential nutrients,

PatchMD empowers individuals to take charge of their health with science-backed supplementation.

For more information about PatchMD’s GLP-1 Support Patches, visit www.patchmd.com.

Source: https://thenewsfront.com/patchmd-introduces-new-glp-1-support-patches-for-individuals-on-weight-loss-medications/

CONTACT: PatchMD
750 East Pilot Rd. STE. B
Las Vegas
NV 89119
United States

323 898 8920

https://www.patchmd.com/

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

51 minutes ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

51 minutes ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

51 minutes ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

51 minutes ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

51 minutes ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

51 minutes ago